Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Noxopharm Announces Principal Investigator Discusses LuPIN-1 Study (ASX:NOX)

Lu-PIN-1 Study two-thirds enrolled Study testing ability of Veyonda to boost effect of Novartis experimental drug Noxopharm to initiate LuPIN-2 study. SYDNEY, January 14, 2019: Noxopharm (...read more

Noxopharm Announces DARRT-1 Study to Advance on Basis of Positive Clinical Data (ASX:NOX)

Trial to enrol final 12 patients at 1200mg dose Based on positive safety and clinical response data Next scheduled review late-January 2019 SYDNEY, December 11, 2018: Noxopharm (ASX:NOX) a...read more

Noxopharm Announces Positive Data from CEP-1 Study of Veyonda (ASX:NOX)

Final CEP-1 data confirm tolerability of Veyonda alone and in combination with carboplatin Halt in progression of cancer growth in 50% of patients Study provides proof-of-concept for well-tol...read more

Noxopharm, 2018 Annual General Meeting Presentation (ASX:NOX)

Noxopharm at-a-glance Australian biotechnology company. Offices Sydney, New York, Hong Kong Playing to our strength.... isoflavonoid drug platform Aiming to bring Veyonda® to market as...read more

Noxopharm to Present Clinical Data at COSA 2018 Annual Meeting (ASX:NOX)

Clinical Oncology Society of Australia Provides updates on CEP-1 and DARRT-1 clinical studies Confirms tolerability of Veyonda Evidence of durable halt of tumour progression in both studi...read more

Noxopharm Releases Latest Corporate Presentation November 2018 (ASX:NOX)

Investment Highlights Leader in the development of isoflavonoid-based therapeutics, an emerging field of drug development - Novel family of G-protein inhibitors blocking key signaling pathways ...read more

Noxopharm Releases September Quarter 2018 Appendix 4C (ASX:NOX)

Sydney, 26 October 2018: Noxopharm (ASX:NOX) today releases its Appendix 4C for the quarter ended 30 September 2018, as well as providing guidance on the next 12-18 months. This report is presented...read more

Noxopharm Announces Key Executive Appointment (ASX:NOX)

Chief Medical Officer appointed Early clinical trial data leads to expanded clinical trial program Company prepares for pre-commercial phase Sydney, 22 October 2018: Noxopharm (ASX:NOX) is...read more

Noxopharm Releases Report on Key Progress of Subsidiary Nyrada (ASX:NOX)

Important progress reported across the Nyrada therapeutic pipeline Potential first-in-class drugs in development for multiple large underserved indications, including cardiovascular disease, stro...read more

Noxopharm, 2018 Annual Report (ASX:NOX)

CHAIRMAN'S LETTER Dear Shareholder, This financial year has been one of increasing momentum for Noxopharm with three clinical studies underway, important additional programs being planned, a...read more

Noxopharm Subsidiary Announces Important Drug Discovery (ASX:NOX)

- New family of drug candidates inhibit the ‘master switch’ involved in inflammation and autoimmunity - Able to cross the blood-brain barrier and blood-nerve barriers - Opens develop...read more

Noxopharm to Support Expanded LuPIN Study (ASX:NOX)

St Vincent’s Hospital, Sydney Phase 1 study in late- stage prostate cancer Combination Veyonda and Lu-PSMA-617 therapy Safety acceptable to date Patient numbers increased from 16 to 32 ...read more

NuEnergy Announces Memorandum of Understanding Signed for Interest to Participate in its Indonesian Coal Bed Methane Exploration and Production (ASX:NGY)

NuEnergy Gas Limited (ASX:NGY)(“NuEnergy” or “the Company”) is pleased to announce that it has signed a Memorandum of Understanding (“MOU”) with EPI Energy Holdings...read more

Noxopharm: Nyrada, NOX’s Subsidiary Non-oncology Company, Announces Key Progress with its Cholesterol-lowering Drug Candidate (ASX:NOX)

NYX-330 designed as small molecule, oral PCSK9 inhibitor Passes initial critical pre-clinical tests of effectiveness Intended for use in combination with statin drugs to achieve substantial f...read more

Noxopharm Announces Veyonda Registered Trade Mark for NOX66 (ASX:NOX)

Sydney, 20 August 2018: Noxopharm (ASX:NOX) today announces that the trade mark, VeyondaTM, has been approved in Australia as part of a world-wide application. NOX66 is due to embark next year on its ...read more

Viewing: 1 - 15 of 200 Previous | Next